Blog
RSS FeedPosted by Michael Wonder on 17 Mar 2019
Toward a strategy to involve patients in health technology assessment in Spain
14 March 2019 - The aim of this study was to develop a feasible and effective strategy to involve patients in ...
Posted by Michael Wonder on 06 Mar 2019
Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage
5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 21 Feb 2019
How big pharma donations may influence public drug coverage
21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should ...
Posted by Michael Wonder on 18 Feb 2019
Medicines for rare disorders
13 February 2019 - PHARMAC is working on policy and funding for medicines for rare disorders. ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 14 Feb 2019
Rationing of health care in the United States; an inevitable consequence of increasing health care costs
13 February 2019 - The modern era of medicine began in the 1960s. Health care coverage expanded with the passage ...
Posted by Michael Wonder on 13 Feb 2019
PHARMAC to review its practices following criticism of breast cancer drug funding
13 February 2019 - The government's drug-buying agency has announced it has begun an internal review following a petition and ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...
Posted by Michael Wonder on 10 Feb 2019
Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology
7 February 2019 - Patient involvement in drug evaluation decision making is increasing. ...
Posted by Michael Wonder on 04 Feb 2019
Time for inquiry into PHARMAC's funding of cancer drugs
4 February 2019 - Labour promised voters world class cancer care but, of all the rocks I've looked under, I ...
Posted by Michael Wonder on 22 Jan 2019
FDA chief Scott Gottlieb warns 'we have many hard decisions ahead of us' if government shutdown persists
18 January 2019 - "We are in uncharted territory. This is a watershed moment in the life of this agency," he ...
Posted by Michael Wonder on 18 Jan 2019
Reducing the expert halo effect on Pharmacy and Therapeutics Committees
18 January 2019 - At a recent pharmacy and therapeutics committee meeting, a highly respected specialist presented a novel haemostatic drug ...
Posted by Michael Wonder on 04 Jan 2019
Decision criteria that influence managed entry agreements
3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties. ...
Posted by Michael Wonder on 13 Dec 2018
ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives
12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of ...